Benzinga | May 6, 2021 04:32PM EDT

Cardiovascular Systems Sees Q4 Sales $67M-$70M vs $69.78M Est.

Fiscal 2021 Fourth Quarter Guidance

For the fiscal 2021 fourth quarter ending June 30, 2021, CSI anticipates:

* Revenue of $67 million to $70 million, representing sequential revenue growth of 6% to 11% compared to the third quarter of fiscal 2021;

* Gross profit as a percentage of revenues in the 70% to 71% range*;

* Operating expenses in a range of $53.5 million to $55.5 million;

* Net loss in a range of $6.0 to $7.0 million; and

* Adjusted EBITDA loss of $1.0 million to $2.0 million.